Putting More Weight on Obesity Trials in Heart Failure

Josephine Harrington; Naveed Sattar; G Michael Felker; James L Januzzi; Carolyn S P Lam; Neha J Pagidipati; Ambarish Pandey; Harriette G C Van Spall; Darren K McGuire

doi:10.1007/s11897-024-00655-z

Putting More Weight on Obesity Trials in Heart Failure

Curr Heart Fail Rep. 2024 Jun;21(3):194-202. doi: 10.1007/s11897-024-00655-z. Epub 2024 Apr 15.

Authors

Josephine Harrington^{1

2}, Naveed Sattar³, G Michael Felker^{4

5}, James L Januzzi^{6

7}, Carolyn S P Lam^{7

8}, Neha J Pagidipati^{4

5}, Ambarish Pandey⁹, Harriette G C Van Spall^{6

10

11}, Darren K McGuire^{9

12}

Affiliations

¹ Division of Cardiology, Department of Internal Medicine, Duke University Medical Center, Durham, NC, USA. josephine.harrington@duke.edu.
² Duke Clinical Research Institute, 300 W. Morris St, Durham, NC, 27701, USA. josephine.harrington@duke.edu.
³ School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
⁴ Division of Cardiology, Department of Internal Medicine, Duke University Medical Center, Durham, NC, USA.
⁵ Duke Clinical Research Institute, 300 W. Morris St, Durham, NC, 27701, USA.
⁶ Baim Institute for Clinical Research, Boston, MA, USA.
⁷ Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁸ National Heart Centre Singapore and Duke-National University of Singapore, Bukit Merah, Singapore.
⁹ Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
¹⁰ Research Institute of St. Joe's, Hamilton, Canada.
¹¹ McMaster University, Hamilton, Canada.
¹² Parkland Health and Hospital System, Dallas, TX, USA.

PMID: 38619690
DOI: 10.1007/s11897-024-00655-z

Abstract

Purpose of review: To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure.

Recent findings: Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.

Keywords: Clinical trial; Heart failure; Obesity; Weight loss.

Publication types

Review

MeSH terms

Clinical Trials as Topic
Heart Failure* / drug therapy
Heart Failure* / physiopathology
Humans
Obesity* / complications
Obesity* / drug therapy
Stroke Volume / physiology
Weight Loss*